THE ROLE OF FENOFIBRATE (TRICOR) IN THE COMPLEX TREATMENT OF MICROANGIOPATHIC COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES

Abstract

The results of numerous studies convincingly prove that fenofibrate, by affecting the activity of PPAR receptors, has hypolipidemic, anti-inflammatory and antioxidant effects. Activation of PPAR receptors in the liver leads to a decrease in the level of lipids that cause atherosclerosis (VLDL, small dense LDL), and an increase in the level of antiatherogenic HDL. Activation of PPAR-α in vascular cells allows to reduce the activity of inflammatory markers, such as C-reactive protein, tumor necrosis factor-β, interleukin-6, fibrinogen, etc. These advantages ultimately reduce the risk of development and progression of macro- and microvascular complications in diabetes mellitus.This abstract will review Evidence-based summary of the efficacy of fenofibrate (Tricor) in the complex treatment of microangiopathic complications in patients with type 2 diabetes.